These data have been established in comparable studies (Schittenhelm et al., 2008; Rauscher et al., 2014; Camacho-Urkaray et al., 2018; Manocha and Jain, 2019), indicating that glial tumors especially of high-grade could be candidates for WT1-targeting cancer immunotherapy. This evidence concerns the gene WT1 and glioma.